Skip to main content

Table 3 Patient characteristics for breast cancer intrinsic subtypes defined by six biomarkers a

From: Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index

Characteristics

Luminal A and luminal B

(N = 916)

Luminal HER2 (N = 77)

HER2-enriched

(N = 74)

Basal-like

(N = 133)

TNP nonbasal

(N = 49)

Ki-67 <14% (N = 540)

Ki-67 ≥14% (N = 376)

P b

Ki-67 <14% (N = 18)c

Ki-67 ≥14% (N = 57)c

P b

Ki-67 <14% (N = 24)

Ki-67 ≥14% (N = 50)

P b

Ki-67 <14% (N = 13)

Ki-67 ≥14% (N = 120)

P b

Ki-67 <14% (N = 25)d

Ki-67 ≥14% (N = 23)d

P b

Age (years), n (%)

 <40

33 (6.1)

32 (8.5)

NS

2 (11.1)

10 (17.5)

NS

2 (8.3)

5 (10.0)

NS

1 (7.7)

18 (15.0)

NS

4 (16.0)

4 (17.4)

NS

 40 to 55

197 (36.5)

139 (37.1)

 

5 (27.8)

24 (42.1)

 

9 (37.5)

25 (50.0)

 

3 (23.1)

47 (39.2)

 

6 (24.0)

11 (47.8)

 

 >55

310 (57.3)

205 (54.4)

 

11 (61.1)

23 (40.4)

 

13 (54.2)

20 (40.0)

 

9 (69.2)

55 (45.8)

 

15 (60.0)

8 (34.8)

 

Menopausal status, n (%)

 Premenopausal

172 (31.9)

130 (34.7)

NS

6 (33.3)

25 (43.9)

NS

9 (37.5)

28 (56.0)

NS

4 (30.8)

50 (41.7)

NS

8 (32.0)

9 (39.1)

NS

 Postmenopausal

360 (66.6)

242 (64.3)

 

11 (61.1)

32 (56.1)

 

15 (62.5)

22 (44.0)

 

9 (69.2)

70 (58.3)

 

17 (68.0)

13 (56.5)

 

 NA

8 (1.5)

4 (1.1)

 

1 (5.6)

–

 

–

–

 

–

–

 

–

1 (4.3)

 

Tumor size (cm), n (%)

 <2

250 (46.4)

158 (42.1)

NS

8 (44.2)

18 (31.6)

NS

6 (25.0)

11 (22.0)

NS

2 (15.4)

30 (25)

NS

6 (24.0)

6 (26.1)

NS

 2 to 5

261 (48.2)

198 (52.5)

 

9 (50.0)

36 (63.2)

 

14 (58.3)

31 (62.0)

 

10 (76.9)

77 (64.2)

 

17 (68.0)

12 (52.2)

 

 >5

22 (4.1)

14 (3.7)

 

–

3 (5.3)

 

45 (16.7)

7 (14.0)

 

–

8 (6.7)

 

1 (4.0)

5 (21.7)

 

 NA

7 (1.3)

6 (1.6)

 

1 (5.6)

–

 

–

1 (2.0)

 

1 (7.7)

5 (4.2)

 

1(4.0)

–

 

Tumor grade, n (%)

 1

144 (26.7)

39 (10.4)

<.0001

1 (5.9)

2 (3.8)

.004

1 (4.2)

–

NS

–

1 (0.8)

NS

1 (4.0)

–

.005

 2

311 (57.5)

226 (60.0)

 

15 (88.2)

26 (50.0)

 

12 (50.0)

17 (34.0)

 

4 (30.8)

32 (26.7)

 

15 (60.0)

6 (26.1)

 

 3

47 (8.7)

91 (24.3)

 

1 (5.9)

24 (46.2)

 

9 (37.5)

31 (62.0)

 

8 (61.5)

75 (625)

 

5 (20.0)

15 (65.2)

 

 NA

38 (7.1)

20 (5.3)

 

–

–

 

2 (8.3)

2 (4.0)

 

1 (7.7)

12 (10.0)

 

4 (16.0)

2 (8.7)

 

Lymph nodes, n (%)

 0

293 (54.2)

192 (50.9)

NS

9 (50.0)

31 (54.4)

NS

6 (25.0)

17 (34.0)

NS

3 (23.1)

64 (53.3)

NS

10 (40.0)

13 (56.5)

NS

 1 to 3

145 (26.9)

109 (29.1)

 

7 (38.9)

18 (31.6)

 

9 (37.5)

10 (20.0)

 

5 (38.5)

32 (26.7)

 

8 (32.0)

4 (17.4)

 

 ≥4

101 (18.7)

73 (19.5)

 

2 (11.1)

8 (14.0)

 

9 (37.5)

22 (44.0)

 

5 (38.5)

23 (19.2)

 

6 (24.0)

4 (17.4)

 

 NA

1 (0.2)

2 (0.5)

 

–

–

 

–

1 (2.0)

 

–

–

 

1 (4.0)

2 (8.7)

 

Chemotherapy, n (%)

 No

275 (50.8)

174 (46.1)

NS

8 (44.4)

16 (28.1)

NS

2 (8.3)

11 (22.0)

NS

2 (15.4)

16 (13.3)

NS

7 (28.0)

7 (17.4)

NS

 Yes

260 (48.2)

199 (53.1)

 

10 (55.6)

41 (71.9)

 

21 (87.5)

38 (76.0)

 

11 (84.6)

102 (85.0)

 

18 (72.0)

19 (82.6)

 

 NA

5 (0.9)

3 (0.8)

 

–

–

 

1 (4.2)

1 (2.0)

 

–

2 (1.7)

 

–

–

 

Hormonotherapy, n (%)

 No

106 (19.5)

67 (17.6)

NS

4 (22.2)

13 (22.8)

NS

18 (75.0)

32 (64.0)

NS

9 (69.2)

86 (71.7)

NS

10 (40)

14 (60.9)

 

 Yes

432 (80.1)

307 (81.9)

 

14 (77.8)

44 (77.2)

 

6 (25.0)

18 (36.0)

 

4 (30.8)

34 (28.3)

 

15 (60)

9 (39.1)

 

 NA

2 (0.4)

2 (0.5)

 

–

–

 

–

–

 

–

–

 

–

–

 

Local therapy, n (%)

 Mastectomy alone

172 (31.9)

105 (28.0)

 

7 (38.9)

14 (24.6)

 

12 (50.0)

16 (32.0)

 

5 (38.5)

28 (23.3)

 

15 (60.0)

8 (34.8)

 

 Mastectomy + RT

61 (11.3)

36 (9.6)

NS

1 (5.6)

5 (8.8)

NS

6 (25.0)

11 (22.0)

NS

3 (23.1)

17 (14.2)

NS

4 (16.0)

6 (26.1)

NS

 Lumpectomy alone

28 (5.2)

13 (3.5)

 

1 (5.6)

4 (7.0)

 

–

4 (8.0)

 

–

5 (4.2)

 

–

–

 

 Lumpectomy + RT

279 (51.6)

222 (58.9)

 

9 (50.0)

34 (59.6)

 

6 (25.0)

19 (38.0)

 

5 (38.5)

70 (58.3)

 

6 (24.0)

9 (39.1)

 
  1. aHER2, human epidermal growth factor receptor 2; NA, not available; NS, not significant; RT, radiotherapy. bP values were calculated using the χ2 test. cTwo cases with Ki-67 NA. dOne case with Ki-67 NA.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us